Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade C 20.17 5.55% 1.06
ACAD closed up 5.55 percent on Friday, September 21, 2018, on 5.43 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ACAD trend table...

Date Alert Name Type % Chg
Sep 21 New Uptrend Bullish 0.00%
Sep 21 Pocket Pivot Bullish Swing Setup 0.00%
Sep 21 Volume Surge Other 0.00%
Sep 21 Calm After Storm Range Contraction 0.00%
Sep 21 Doji - Bearish? Reversal 0.00%
Sep 21 Upper Bollinger Band Walk Strength 0.00%
Sep 21 Multiple of Ten Bullish Other 0.00%
Sep 21 Wide Bands Range Expansion 0.00%
Sep 21 Above Upper BB Strength 0.00%
Sep 21 Overbought Stochastic Strength 0.00%

Older signals for ACAD ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 41.2
52 Week Low 12.77
Average Volume 2,711,474
200-Day Moving Average 21.0946
50-Day Moving Average 15.0158
20-Day Moving Average 14.742
10-Day Moving Average 15.156
Average True Range 0.8866
ADX 27.48
+DI 54.8695
-DI 10.9378
Chandelier Exit (Long, 3 ATRs ) 17.8002
Chandelier Exit (Short, 3 ATRs ) 15.8298
Upper Bollinger Band 18.0963
Lower Bollinger Band 11.3877
Percent B (%b) 1.31
BandWidth 45.506716
MACD Line 0.6779
MACD Signal Line 0.0197
MACD Histogram 0.6581
Fundamentals Value
Market Cap 2.47 Billion
Num Shares 122 Million
EPS -2.53
Price-to-Earnings (P/E) Ratio -7.97
Price-to-Sales 67.33
Price-to-Book 10.21
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.12
Resistance 3 (R3) 22.00 21.23 21.80
Resistance 2 (R2) 21.23 20.73 21.29 21.69
Resistance 1 (R1) 20.70 20.43 20.97 20.82 21.58
Pivot Point 19.93 19.93 20.06 19.99 19.93
Support 1 (S1) 19.40 19.43 19.67 19.52 18.76
Support 2 (S2) 18.63 19.13 18.69 18.65
Support 3 (S3) 18.10 18.63 18.55
Support 4 (S4) 18.22